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Acronym Definition 
AE Adverse events 
AMSTAR 
APR 
Assessing the quality of systematic reviews 
Abdominoperineal resection 
ASA American Society of Anesthesiologists classification,  
BMI Body mass index (kg/m
2
) 
CG 
CPA 
Clinical guideline 
Colo-anal J-pouch anastomosis 
DH 
ECOG 
Department of Health 
Eastern Cooperative Oncology Group 
EORTC-
QLQ 
European organisation for research and treatment of cancer core quality of life 
questionnaire 
EQ-5D 
FACT-C 
FACT-EW 
FCSI 
FIQL 
FISI 
EuroQol 5 dimensions 
Functional assessment of cancer therapy - colorectal 
Functional assessment of cancer therapy  W emotional well-being 
FACT colorectal symptom index 
Faecal incontinence quality of life 
Faecal incontinence severity index 
FR 
FU 
Future research 
Fluorouracil 
HADS Hospital anxiety and depression scale 
HRQoL Health related quality of life   
HS Health states 
HTA Health technology assessment 
HUI Health Utility Index 
HUI2 Health Utility Index mark 2 
HUI3 
LCR 
LRA 
LV 
Health Utility Index mark 3 
Laparoscopic colon resection 
Transanally double stapled low colorectal anastomosis 
Leucovorin 
MDT Multi-disciplinary team 
MTA Multiple technology assessment 
NCA National Clinical Audit 
NHS National Health Service 
NICE National Institute for Health and Care Excellence 
OS 
PANAS 
PANSS 
Overall survival 
Positive and negative affect scale 
Positive and negative syndrome scale 
PFS Progression free survival 
PR Potential recommendations 
PROM(s) patient reported outcome measure(s) 
R&D Research and development 
RCT 
RSCL 
Randomised controlled trial 
Rotterdam symptom checklist 
SF-6D Short form 36 
SG Standard gamble 
STA Single technology assessment 
TA Technology Appraisal 
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TAG 
TEM 
TME 
TNM 
Technology Assessment group 
Transanal endoscopic microsurgery 
Total mesorectal excision 
Tumour, node, metastases 
TTO Time trade off 
UK United Kingdom 
VAS Visual analogue scale 
WP Work package 
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1. BACKGROUND 
EEPRU was approached by Jason Cox (R&D Division) to prepare a programme of research to support 
the appropriateness of, and use of, patient reported outcome measures (PROMs) collected for the 
National Clinical Audit (NCA).  The EEPRU programme was informed by a Research and Development 
(R&D) template prepared by Simon Bennett, Steve Fairman and Keith Willett at NHS England. 
 
The purpose of introducing PROMs into the NCA programme is to be able to 1) compare 
performance between providers and commissioners in the National Health Service (NHS), 2) 
compare the cost-effectiveness of alternative providers in delivering the specific services (i.e. linking 
outcomes and resource use), and 3) assess the cost-effectiveness of alternative interventions and 
other changes in the NHS.  The intention is to introduce PROMs across a range of conditions over the 
next 3 years commencing with 13 conditions in the 2014/15 NCA programme.  
 
The agreed research programme consists of 3 concurrent work packages (WP) as described in the 
document submitted to the DH (8
th
 November 2013).  The current document provides details on the 
objectives, methodology and results for Work Package 1 (WP1): to determine what PROMS should 
be used in the 13 health conditions specified in the 2014/15 NCA programme. 
 
2. OVERVIEW 
WP1 is split into three separate components consisting of: 
WP1.1 To examine whether the EQ-5D is appropriate in the 13 health conditions specified in the 
2013/14 NCA programme.  
WP1.2 To identify what measure could be used when the EQ-5D is not appropriate in the 13 health 
conditions, taking into account that the proposed measure would be used to generate 
preference-based utility measures (either directly through existing preference-based weights, 
or indirectly through existing mapping functions suitable for the proposed measure). 
WP1.3 To identify the evidence required to address questions of cost-effectiveness using the NCA 
data. 
 
Each component consists of a series of reviews of the literature. 
 
This Appendix provides the detailed results for the condition bowel cancer and should be read in 
conjunction with both the main report and the methods/search strategy appendices. 
 
7 
 
3. METHOD 
The full detailed methodology used is provided in Appendix A, including the search strategy, 
selection criteria for studies included, and data extraction etc.  In summary, a review of the literature 
was undertaken to assess the appropriateness of the EQ-5D in terms of classic psychometric criteria 
(WP1.1); where the EQ-5D was not considered appropriate, additional searches were undertaken to 
identify alternative measures (WP1.2); and finally, existing health technology appriasials were 
reviewed and data requirements were compared with variables currently collected in the IBD audit 
(WP1.3).   
 
3.1 Psychometric properties (WP1.1) 
Assessments reported in the included studies were categorised according to the following 
definitions: 
 
Acceptability 
Data relating to how acceptable the measure was to the person completing it, expressed as the 
proportion of completed surveys, or the proportion of missing data. 
 
Reliability 
There are two main definitions for reliability, a) the degree to which a measure reproduces the same 
results in an unchanged population and b) the degree to which a measure reproduces the same 
results when completed by different assessors (e.g. patient and proxy report). In both cases, 
reliability can be assessed by re-testing, and calculating the correlations or difference between tests. 
In case a) the comparison may be between the same populations separated by time, where no 
change in health state was observed (as compared to using an alternative condition specific or 
generic measure). In case b) the measure may be completed by multiple people (proxies) on the 
ƉĂƚŝĞŶƚ ?Ɛ ďĞŚĂůĨ ĂŶĚ ƚŚĞŝƌ ƌĞƐƉŽŶƐĞƐ ĐŽŵƉĂƌĞĚ ǁŝƚŚ ƚŚŽƐĞ ŽĨ ƚŚĞ ƉĂƚŝĞŶƚ ? tŚĞƌĞ ƚŚĞ ŽƵƚĐŽŵĞ
measure is specifically designed for self-report by patients, this test of reliability may be expected to 
produce less agreement.  
 
Construct validity 
This is an assessment of how well an instrument measures what it intends to measure. Two main 
definitions are used in this review.  
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a) Known group validity, where estimates for groups that are known to differ in a concept of interest 
are compared either qualitatively or statistically. The known groups may be defined using other 
measures, according to clinical categorisation.  
b) Convergent validity assesses the extent to which a measure correlates with other measures of the 
same or similar concepts. Correlation coefficients were considered low if <0.3, moderate if between 
0.3 and 0.5, and strong when >0.5.  
 
Responsiveness 
a) Change over time. This is an assessment of whether measurements using the instrument can 
detect a change over time, where a change is expected. This may be before and after an 
intervention, or through progression of a disease. Evidence was considered to be good where a t-
test was significant, though weaker evidence to support responsiveness was considered where there 
was a change in the expected direction, but was not statistically significant or not tested. Effect size 
and standardised response mean were also acceptable assessments of responsiveness.  
b) Ceiling and floor effects were also considered to be indicators of responsiveness. Assessments of 
ceiling effects include the proportion of patients who score full health within a group of patients 
with known health detriments. A ceiling or floor effect can affect the sensitivity of the measure in 
detecting changes over time in patients at the extremes of the measure (for example those with 
severe disease activity and those with just minor symptoms of the condition). 
 
3.2 Alternative measures (WP1.2) 
No alternative measure searches were performed.  
 
3.3 Evidence required for economic evaluations (WP1.3) 
The existing HTAs were reviewed alongside the variables currently collected in the NCA to determine 
if clinical or PROM data routinely collected in the NCAs would suffice to address questions of cost-
effectiveness, and to identify any gaps in the evidence that would be required to compare providers, 
or the cost-effectiveness of interventions or policies. 
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4. RESULTS FOR BOWEL CANCER 
4.1 Evidence of appropriateness of EQ-5D in bowel cancer (WP1.1) 
4.1.1 Selection of systematic review 
Two systematic reviews were identified through expert sources.(1;2) The process of selection of the 
most appropriate review is documented in Table 1. 
 
Table 1: Selection of most appropriate review for bowel cancer 
Review Search date Relevance of 
review 
Quality of 
search 
Quality of 
review 
Selection 
Oxford 
(2010)(2) 
February 2010 Question 
relevant, data 
detail poor 
Reliance on 
pre-existing 
database, ovid 
strategy not 
provided. 
However, 
probably 
adequate. 
QA performed; 
search numbers 
provided; 
unclear if single 
reviewer DE 
and SS; 
synthesis 
methods 
unclear 
 
NICEQoL 
2014(1) 
August 2010 Question 
relevant, some 
data detail 
available 
Searched 7 
databases. 
Supplementary 
searches in 
Euroqol 
database for 
EQ-5D 
QA performed; 
details of 
search numbers 
provided; 
unclear if single 
reviewer SS, 
one reviewer 
DE; narrative 
synthesis 
Include  W more 
recent than 
Oxford 
2010,(2)more 
DE detail, more 
transparent 
search methods 
QA, quality assessment; SS, study selection; DE, data extraction 
 
4.1.2 Structured abstract for Longworth et al 2014(1) 
Purpose of review 
The review aimed to investigate the appropriateness of three generic preference-based health 
related quality of life (HRQOL) measures (EuroQoL 5 dimensions (EQ-5D), health utility index (HUI-3), 
and short-form 6 dimension (SF-6D)) for a range of health conditions: vision loss, hearing loss, skin 
disorder and cancer (bowel, head and neck). This review is only concerned with the results relating 
to bowel cancer.  
 
Methods of review 
Search and study selection: Seven electronic databases were searched from inception: BIOSIS, 
CINAHL, Cochrane Library, EMBASE, MEDLINE, PsychInfo and Web of Science.  Electronic searches 
were conducted in August 2010. Four sets of search strategies were developed, one for each of the 
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four health conditions. Search strategies combined terms relating to the health condition with terms 
for the three HRQOL measures. The full search strategies were listed.  
 
Inclusion criteria: Studies were included in the review if they satisfied the following criteria: they 
contained HRQoL data as measured by one of the three generic HRQoL instruments, namely SF-6D, 
HU13 or EQ-5D; the study reported results for another HRQoL measure or a disease-specific 
measure to enable assessment of validity, responsiveness or reliability of the EQ-5D; individuals with 
one of the four conditions of interest, namely vision disorders, hearing disorders, skin disorders, or 
cancer. All study types were included. 
 
Exclusion criteria: Studies not in the English language.  
 
Data extraction and synthesis: Data were extracted by one reviewer using a newly developed 
standardised form, designed for specific use in the review. Data were tabulated by condition and 
presented as a narrative synthesis. In addition, results by condition were reported separately 
according to the construct measured, namely construct validity, reliability and responsiveness.  
Construct validity was measured either using the known-groups methods, or by evaluating 
convergent validity. The review used the following categories for evidence of correlation: >0.5 was 
ƐƚƌŽŶŐ ? AM ? ? ? ƚŽ A? ? ? ? ŵŽĚĞƌĂƚĞ ? AM ? ? ? ůŽǁ ? ^ĞĐŽŶĚůǇ, responsiveness was assessed where data 
allowed. Responsiveness was defined as the ability to which an instrument can detect a clinically 
significant or practically important change in health utility over time.  
 
ƵƚŚŽƌƐ ? ĐŽŶĐůƵƐŝŽŶƐ ? The authors of Longworth et al. 2014a concluded that the evidence for the 
appropriateness of the EQ-5D was generally satisfactory, with positive evidence of the construct 
validity of the EQ-5D but insufficient evidence to support the responsiveness of the EQ-5D for this 
health condition.    
 
 
4.1.3 Assessment of the review in relation to objectives of work package 1.1 
Relevance of review question: The aim of Longworth et al. 2014 was to assess whether the three 
HRQoL measures were appropriate for use for four specific conditions. Whilst only one subgroup of 
one of these conditions is relevant to the aims of WP 1.1 (specifically bowel cancer), the inclusion 
criteria and methods used for assessment of these relevant conditions are concordant with WP 1.1. 
Only data relating to bowel cancer will be reported in the following section.  
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Assessment of review quality:  The assessment was conducted using a modified version of the 
 ‘ĂƐƐĞƐƐŝŶŐ ƚŚĞmethodological ƋƵĂůŝƚǇ ŽĨ ƐǇƐƚĞŵĂƚŝĐ ƌĞǀŝĞǁƐ ?  ?AMSTAR) tool (3) and also by 
considering the strength and quantity of the evidence. The adequacy of the reported data in the 
context of work package 1.1 was also assessed.  A summary of the quality assessment is shown in 
Table A7. 
 
Longworth et al. (1) scored well against most of the relevant AMSTAR criteria. A full study protocol is 
published with the review to evidence an a priori design, therefore reducing the possibility of the 
existence of reporting bias. Quality assessment of the included studies was conducted however no 
formal tool was used for this purpose. The authŽƌƐƐƚĂƚĞƚŚĂƚĂ ‘ũƵĚŐŵĞŶƚƌĞŐĂƌĚŝŶŐƚŚĞƌŝƐŬŽĨďŝĂƐ
of each study was determined by reviewing methods of patient recruitment, and noting any missing 
data reported (either study drop-ŽƵƚƐŽƌŝŶĐŽŵƉůĞƚĞƋƵĞƐƚŝŽŶŶĂŝƌĞƐ ? ?(1). Study selection was carried 
out by only one reviewer, and double data extraction or data-checking was not conducted, leaving 
the study at higher risk of errors. Inclusion criteria are clearly defined, however the only exclusion 
criterion provided is that of papers in non-English languages. 
 
Acceptability of the search: Unlike the other reviews, an iterative search approach was applied in the 
review, although this was not fully described. A comprehensive Medline strategy comprising generic 
instrument search terms and condition terms were reported in the review. The search is considered 
comprehensive for the purpose of the review. 
 
Acceptability of study selection: Study selection criteria were clearly defined and concordant with 
the inclusion criteria for WP1.1. Whilst the review covered four health conditions, separate analyses 
were conducted for each and therefore study selection was acceptable. 
 
Adequacy of available data and synthesis:  The review provided sufficient data on each of the 
properties of interest and was therefore adequate for the requirements of WP1.1. 
 
In conclusion, the methods employed in the review were generally of an acceptable quality and 
designed to meet the requirements of WP1.1. However, the study search was conducted in 2010, 
and as such an update search was conducted, and any new studies integrated with the findings of 
Longworth et al.(1) 
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A total of 98 studies were included in the Longworth review, reporting results for 20 different types 
of cancer.  The authors report 11 of these studies evaluated the construct validity or responsiveness 
of the EQ-5D, SF-6D or HUI-3 for colon cancer.(4-14) One study reports data for HUI3 only (i.e. no 
EQ-5D data),(12) and one study is reported in study characteristics only, with no associated outcome 
data so is not included here.(13) 
 
From a total of 76 titles identified in the update search, no additional studies met the inclusion 
criteria for WP1.1. Therefore a total of nine studies with data relating to EQ-5D are included in this 
review.  Of the nine included studies, one study is explicitly reported to have used the UK EQ-5D 
tariff (10). No further details of EQ-5D versions are provided for the remaining studies. Three studies 
were conducted in the UK (4;9;10). The majority of the remaining studies were conducted in other 
European countries, one in Sweden;(8) and three in the Netherlands.(5;6;11) One study was 
conducted in Japan (7), and one study was multinational.(14) 
 
Details of patient characteristics were not reported in great detail in the review, for example no 
details of sex or age were given.  All studies included patients with colorectal cancer. In seven 
studies patients were undergoing or had recently undergone surgery (4-9;11), whilst in two studies 
patients were assigned to a pharmaceutical intervention group. (10;14)  
 
Three studies were RCTs (8;10;14), two studies were cross-sectional,(6;11) and four were 
before/after studies.(4;7;9;11) 
 
A range of measures were used to assess the construct validity and/or responsiveness of the EQ-5D. 
Some measures used for comparison were designed for generic cancer use: European Organisation 
for Reseach and Treatment of cancer (EORTC)(6;8;14), or EORTC-QLQ.(5)  Two studies used 
measures designed for use in generic cancer therapy functional assessment of cancer therapy  W 
emotional well-being, and colorectal cancer (FACT-EW),(4) FACT-C(9). Doornebosch et al.(11) 
compared the EQ-5D with a condition specific measure, the Faecal Incontinence Quality of Life 
(FIQL), and Siena et al.(14) used the FACT Colorectal Symptom Index (FCSI). Wilson et al. compared 
the EQ-5D with other generic HRQoL measures (SF-12 and EORTC QLQ),(9) whilst Sharma et al. 
assessed the EQ-5D in relation to tools designed to assess mood, Positive and Negative Syndrome 
Scale (PANSS), and Hospital Anxiety and Depression Scale HADS.(4) The evidence is presented in 
accordance with the definitions of psychometric properties given in Section 3.1.2. 
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Construct validity (known group): Six studies were identified in the review that evaluated the 
construct validity of the EQ-5D in bowel cancer patients using the known-group method.(5;6;8;9;11) 
Positive evidence for the EQ-5D was reported in two studies.(9;11)  The study by Wilson (2006) 
showed that the EQ-5D was consistent with preoperative EQ-VAS, SF-12 general health, SF-12 PCS 
FACT-C total score and Quality of Life Questionaire (QLQ) general health, with all measures showing 
a significant difference in scores between Easten Cooperative Oncology Group (ECOG) performance 
status groups. Doornebosch (2008) showed that both EQ-5D and FIQL scores were not affected by 
age and gender of the patients, nor by surgical aspects or tumour characteristics. Two further 
studies presented negative evidence for the EQ-5D.(5;6) Doornebosch et al. 2007 reported that the 
EORTC QLQ-CR38 (the colorectal module of the EORTC) showed a significant difference in scores by 
surgical intervention groups for defecation problems, but neither the EQ-5D nor the EORTC QLQ-C30 
detected a statistically significant difference in the overall scores (EQ-5D) or any subscale (EORTC 
QLQ-C30).(5) Gosselink et al. studied the difference in EQ-5D and EORTC scores for three surgical 
intervention groups: Colo-anal J-pouch anastomosis (CPA), abdominoperineal resection (APR), and 
transanally double-stapled low colo-rectal anastomosis (LRA). EQ-5D scores did not differ between 
the three surgical intervention groups, whilst scores on four subscales of the EORTC (global health 
status in the QLQ-C30, and body image, micturition and defacation in the QLQ-CR38) did differ 
significantly in some between-group comparisons.(6) Gosselink et al. also presented some mixed or 
equivocal evidence for the construct validity of the EQ-5D, along with two other studies.(6-8) 
Gosselink et al. found that mean scores on the EQ-5D differed for one of the three surgical 
interventions (CPA), when compared to a sex-age matched general population. Hamashima et al. 
failed to show significant differences on EQ-5D scores between patient groups (with or without 
stoma), though it was unclear if a difference should be expected.(7) Janson et al. reported that the 
EQ-5D did not detect a difference between study groups at baseline, in agreement with findings as 
measured by the EORTC-C30.(8) 
 
Construct validity (convergent):  One study reported results for convergent validity.(4) The EQ-5D 
index score was not significantly correlation with TNM stages (r=0.06, p=0.5), where the HADS 
anxiety score, positive and negative affect schedule (PANAS) negative affect score and FACTC-
emotional wellbeing score showed statistically significant low to moderate correlations (r= 0.345, 
r=0.294, r=-0.354 respectively, p=0.01 for all). However, the HADS depression, PANAS positive affect, 
MRS, FACTC-physical wellbeing, FACTC social and family wellbeing, FACTC functional wellbeing and 
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FACTC- colorectal cancer-specific scores were all non-significantly correlated to TNM (Tumour, Node, 
Metastases) stage as well.   
 
Responsiveness: Five studies were identified in the review that assessed the responsiveness of the 
EQ-5D.(4;8;10;11;14) One study presented positive evidence for the EQ-5D: in an RCT of 
pharmaceutical interventions, Anderson and Palmer (1998) showed statistically significant changes 
in EQ-5D scores 2 weeks post baseline in favour of patients in the raltitrexed group, showing 
improvements for mobility and usual activities, and for general health. Statistically significantly 
different changes were reported at 2 weeks in the raltitrexed and the 5-FU+LV (fluorouracil + 
leucovorin) groups using the Rotterdam Symptom Checklist (RSCL). These results were no longer 
significant by week 10, although the EQ-5D did show non-significant trends in favour of the 
raltitrexed group. Two studies reported a lack of responsiveness in the EQ-5D.(4;11)  Doornebosch et 
al. reported that significant changes were not detected by the EQ-5D where they were detected by 
the overall Faecal Incontinence Severity Index (FISI), and two of the four dimensions of the Faecal 
Incontinence Quality of Life (FIQL) measure (lifestyle and embarrassment, but not coping and 
depression) 6 months after surgery.(11) Sharma 2007 explored the validity of the EQ-5D in patients 
undergoing elective open resection. EQ-5D scores indicated no significant change over time (in 
keeping with HADS anxiety, both PANAS positive and negative affect scores, mood rating scale, 
FACTC total and trial outcome idex and EQ-VAS) where the HADS depression score did.(4)  Two 
studies reported data that was either mixed or equivocal about the responsiveness of the EQ-
5D.(8;14) Janson et al. (2007) found that in general, the differences in mean scores over time in the 
EQ-5D data follow the same trend as observed in the majority of EORTC symptom and function 
scales with no significant differences reported for either. However, the EQ-5D did not accurately 
detect the very small statistically significant changes in the EORTC scales observed by the emotional 
and social scales, between baseline and week 4.(8) In Siena et al. the EQ-5D was only able to detect a 
statistically significant difference in the treated group whereas improvements in symptoms 
measured by the FACT colorectal symptom index were observed in both the treated and best 
supportive care groups.(14) 
 
4.1.4  Conclusion of appropriateness of EQ-5D in bowel cancer 
The evidence base assessing the performance of the EQ-5D in bowel cancer is of a moderate size 
(N=9), but not all studies assessed all the psychometric properties of the EQ-5D. With the exception 
of one study which used UK preference-based weights,(10) it is unclear which tariff was used. No 
details were provided in Longworth et al. on characteristics such as age.(1)  
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No evidence was reported in the review for either acceptability or reliability of the EQ-5D.  Construct 
validity was explored using known group methods in six studies, and convergent methods in one 
study. The evidence relating to construct validity by known group methods was mixed, with two 
studies reporting that the EQ-5D was able to detect differences between groups where other 
measures did,(9;11) two studies reporting that the EQ-5D failed to detect a difference in groups 
where other measures did,(5;6) one study reporting no differences between groups by the EQ-5D 
and EORTC QLQ-C30(8) and one study reporting no difference in EQ-5D scores between two groups 
where it was not clear if a difference should be expected.(7)  The evidence-base relating to 
convergent validity was small with only one study. This study reported the EQ-5D was not correlated 
with TNM stage where scores from three other measures or subscales were moderately correlated, 
and six other measures or subscales werĞŶ ?ƚ ƐƚĂƚŝƐƚŝĐĂůůǇ ƐŝŐŶŝĨŝĐĂŶƚůǇ ĐŽƌƌĞůĂƚĞĚ ?(4) However, the 
sample size (n=104) may have resulted in under-powering when split across several TNM stages. 
Results relating to responsiveness were also mixed, with one study showing the EQ-5D was able to 
detect a change where another measure did,(10) two studies showing the EQ-5D was not able to 
detect a change where other measures did,(4;11) and two studies showing mixed results where the 
EQ-5D was able to detect some changes but not others.(8;14) 
 
In summary, whilst there is some strong positive evidence to support the use of the EQ-5D in this 
patient group, the negative and mixed evidence suggest that additional validation is required before 
the EQ-5D can be recommended (Table 2).  
 
Table 2: Summary of evidence on EQ-5D for bowel cancer 
Measure (N) Acceptability Reliability Construct (KGV; 
Convergent) 
Responsiveness  
(Change over time; Ceiling 
effects) 
Adults 
EQ-5D (9) Not reported Not 
reported 
Mixed; Poor (n=1)  Mixed; Not 
reported 
 
 EQ-5D requires additional validation. 
 
 
4.2 Alternative measures in bowel cancer (WP1.2) 
Whilst the EQ-5D is considered to require further validation in patients with bowel cancer, 
alternative measures were not reviewed. It is recommended that a cancer specific PROM, the 
European Organization Quality of Life Questionnaire (EORTC QLQ- ? ? ? ĂŶĚ ŝƚ ?Ɛ ƌĞůĞǀĂŶƚbowel-
specific module EORTC CR29 (which supersedes the CR38) is collected alongside the EQ-5D as 
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condition specific measures may be more sensitive to the effects of interventions on the condition 
specific symptoms and the side effects of treatments. 
 
The EORTC QLQ-C30 consists of 30 questions covering function (e.g. cognitive, emotional, physical, 
role, social) and the common cancer symptoms (e.g. fatigue, nausea and vomiting, pain).(15) 
Responses to these are summarised using 14 sub-scales plus a global quality of life scale.(15)  A 
recently developed UK based preference-based utility tariff can be used to generate utility values in 
economic evaluations.(16)  However, it should be noted that the the utility values obtained using 
this tariff are not directly comparable to those generated using the EQ-5D.   
 
The EORTC QLQ-CR38(17)was developed in the Netherlands, and comprises 38 items. Nineteen 
questions are completed by all patients and the other 19 by subgroups of patients such as those with 
or without a stoma. The measure comprises two functional scales (body image and sexuality) and 
seven symptom scales (micturition problems, symptoms in the area of the gastrointestinal tract, 
chemotherapy side-effects, problems with defaecation, stoma-related problems, male and female 
sexual problems). Whilst there is some psychometric data relating to it, it was never fully 
validated.(18) It has been superseded by the CR29, which was developed with patients from the UK, 
France and Germany (19) and has been validated in at least one study,(18) and adapted for use in at 
least two other countries (Spain and Iran).(20;21)  It comprises 29 items relating to colorectal cancer 
and its treatment, including micturition, pain, defecation problems, faecal incontinence, anxiety, 
body image, abdominal bloating, dry mouth, hair loss, taste problems, skin problems, stoma 
embarrassment and stoma problems. Gender-specific sexual items were also included.  
 
 
4.3 Evidence for economic evaluations in bowel cancer (WP1.3) 
4.3.1 Cost-effectiveness modelling approach used in recent HTAs in bowel cancer 
Ten TAs relating to bowel cancer were identified from the searches.  Four of the TAs were 
superseded by more recent publications,(22-25) leaving three MTAs,(26-28) and three STAs.(29-31)  
A clinical guideline (CG) was subsequently identified from the references lists of the included 
studies.(32)  Six of the TAs examined the clinical and cost-effectiveness of pre-specified 
pharmaceutical interventions and one examined the clinical and cost-effectiveness of laparoscopic 
surgery compared to open-resection (Table 3).(27)  While the CG incorporated a broader decision 
area covering both the diagnosis and management of colorectal cancer, their economic model 
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focussed on the costs and effects associated with ten sequences of chemotherapy limited to two 
lines of treatment.(32) 
 
With the exception of the CG, which used a decision tree,(32) state transition models were used to 
examine the cost-effectiveness of the interventions under appraisal.  All seven models comprised of 
discrete health states which represented the clinical pathway for people with bowel cancer at the 
point of the intervention.  The number of health states was typically less than five and the health 
states were predominantly defined in terms of progression or relapse (worsening of cancer 
symptoms) and survival (Figure 1).  Clinical trial data (survival curves and hazard ratios (HR), see 
exemplar provided in Figure 2) were used to inform overall survival (OS), tumour response rates (e.g. 
defined using the RECIST instrument) and progression free survival (PFS).  Treatment specific rates 
for graded adverse events were also sourced from the clinical trials used to inform the effectiveness 
of the interventions.  The TA for laparoscopic surgery used survival curves from RCTs to model OS, 
surgical mortality rates, and recurrence.  Intervention specific rates for non-elective surgery and 
hernias were sourced from the literature. 
 
Figure 1: Modelling approach used in bowel cancer HTAs 
 
Legend: Orange framed boxes with uppercase text describe the health states used in the diabetes TA models 
while the purple framed boxes with lower case text describe the evidence used.  Italised text indicative of 
additional variables which would be informative for future economic evaluations. 
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Figure 2:  Exemplar survival curves used to model interventions in cancer 
 
PFS=Progression free survival 
 
 
All studies quality adjusted survival by assigning mean utility values to the discrete health states.  
With the exception of one appraisal which utilised data from an observational study conducted to 
inform the TA,(31) the utilities were either drawn from the study used to provide the primary clinical 
evidence,(26;30) or were sourced from the literature.(27-29;32)  Rather than modelling the effects 
on HRQoL explicitly in separate health states, adjustments to utilities were applied in some models 
to reflect the prevalent side-effects of treatments for cancer (e.g. skin-related toxicities, 
hypomagnesaemia, paronychia, abdominal pain, diarrhoea and constipation, fatigue) or adverse 
events (e.g. surgical complications).(26;29-32)  None of the studies used EQ-5D data for all the 
utilities within the models and many used utility values which were not weighted by general 
population preferences.  The results of the searches conducted to inform the model parameters 
suggest the volume of EQ-5D data in patients with colorectal cancer is very limited with many of the 
authors recommending this as a future research priority.  It has also been suggested that evidence 
ĐĂƚĞŐŽƌŝƐĞĚďǇƵŬĞ ?ƐƐƚĂŐĞǁŽƵůĚďĞƵƐĞĨƵů ?^ƚĂŐŝŶŐŝƐĐƵƌƌĞŶƚůǇƵƐĞĚĨŽƌĐŚĞŵŽƚŚĞƌĂƉǇůŝĐĞŶƐŝŶŐ
indications and would be useful when modelling the cost-effectiveness of screening interventions; it 
could be linked to audit data to estimate resource usage by stage; and if stage was linked to EQ-5D 
utility values this would also be useful for the future economic models in bowel cancer as this 
evidence is currently not available.[personal communication Dr P Tappenden, ScHARR 3rd June 
2014] 
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Table 3: Summary of existing models used in bowel cancer TAs 
 Model method, clinical effect  Method used to model utilities  
MTA (TA242): Colorectal cancer (metastatic): 3rd line, cetuximab, bevacizumab and panitumumab; 2012(26) 
 TAG State tranisition model  
3 discrete health states: PFS, progressive disease, 
death (progression defined as worsening 
symptoms of cancer) 
Effectiveness: survival curves for OS, response 
(using Dukes stage) and PFS  
Source: RCTs used for clinical effect 
Utility: HUI3; mean values assigned to discrete HS 
Source: RCT used for clinical effect 
AEs: intervention specific utilities used to account for 
differences in treatment toxicity 
CG (CG131): Colorectal cancer: the diagnosis and management of colorectal cancer; 2011(32) 
 Decision tree  
3 discrete health states: stable metastatic 
disease, progressive metastatic disease, death 
Effectiveness: survival curves for OS, response  
and PFS  
Source: RCTs used for clinical effect  
Utility: elicited (TTO) from patients and community 
members; mean values assigned to discrete HS 
Source: published literature
 
AEs: data from patients with metastatic breast cancer 
used to account for treatment toxicities such as 
diarrhoea/vomiting, hand foot syndrome (no details 
on measure/elicitation method) 
STA (TA212): Colorectal cancer (metastatic): bevacizumab; 2010(29) 
 State transition model 
4 discrete health states: 1
st
 line treatment, PFS 
post treatment, progression, death 
Effectiveness: survival curves for OS, response  
and PFS  
Source: RCTs used for clinical effect  
Utility: EQ-5D, HUI, supplemented with expert 
opinion;  mean values assigned to discrete HS 
Source: published literature
 
AEs: assumed higher utility when not on treatment to 
account for intervention toxicity 
STA(TA176): Colorectal cancer (first line)  W cetuximab; 2009(30) 
 State transiition model  
Numerous discrete health states (for each of 1
st
 
to 3
rd
 line therapy): successful resection, 
unsuccessful curative resection (i.e. progression), 
death 
Effectiveness: survival curves for OS, response  
and PFS  
Source: RCTs used for clinical effect 
Utility: EQ-5D, HUI, assumption; mean values 
assigned to discrete HS  
Source: studies used for clinical effect, supplemented 
by published literature
  
AEs: disutilities assumed to be captured in main data 
as from patients receiving first line treatment 
STA (ID514): Colorectal cancer (metastatic) - aflibercept (31) 
 State transition model 
4 discrete health states: no progression on 
treatment, no progression post treatment, 
progressive disease, death 
Effectiveness: survival curves for OS, response  
and PFS  
Source: RCTs used for clinical effect 
Utility: EQ-5D; mean values assigned to discrete HS 
Source: observational utility study, supplemented by 
published literature  
AEs: disutilities assigned using published data for 
treatment toxicity 
MTA(TA105): Colorectal cancer - laparoscopic surgery; 2006(27) 
 TAG semi-Markov model  
5 discrete health states: disease free, treatable 
(surgical or other) recurrence of disease, disease 
free after recurrence, non-operable recurrence, 
death 
Effectiveness: survival curves for OS, surgical 
mortality rates, recurrence; rates for non-elective 
surgery and hernias 
Source: survival curves from RCTs used for 
clinical effect; rates sourced from literature 
Utility: EQ-5D, elicited from oncology nurses (method 
unclear); mean values assigned to discrete HS 
Source: published literature 
AEs: no mention of disutility due to adverse events 
MTA(TA100): Colon cancer (adjuvant) - capecitabine and oxaliplatin; 2006(33)  
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 TAG State transition model  
3 discrete health states: alive without relapse, 
alive post-relapse, death 
Effectiveness: survival curves for OS, response  
and PFS  
Source: RCTs used for clinical effect 
Utility: elicited from patients with colorectal cancer 
using SG; mean values assigned to discrete HS 
Source: published literature 
AEs: no mention of disutility due to treatment toxicity 
HS: health states; AE: Adverse Events; MTA: Multiple Technology Appraisal; STA: Single Technology 
Appraisal; CG: Clinical Guideline; TAG: Technology Appraisal Group; TA: Technology Appraisal; TTO: Time 
trade-off; SG: Standard Gamble; RCT: randomised controlled trial; OS: overall survival; PFS: progression free 
survival 
 
 
In summary, the following evidence would be required to compare providers or the cost-
effectiveness of interventions for bowel cancer: 
 
x Condition severity (e.g. Dukes stage) 
x Tumour location  
x Surgical rates (type of intervention, success rate, post-surgical complication, length of stay) 
x Chemotherapy regimens (medications, adverse events) 
x Radiotherapy (type of intervention, success rates, side-effects) 
x Recurrence/relapse rates (with dates) 
x Utility values 
x Death with cause to model cancer related deaths 
 
The majority of this evidence would need to be dated and linked through timings of collection.  
 
 
4.3.2 Fields collected in the bowel cancer NCA  
All patients
1
 with a diagnosis of bowel cancer admitted for the first time to a NHS Trust in England or 
a Health Board in Wales are eligible for inclusion in the bowel cancer audit.  The fields in the bowel 
cancer NCA are collected via an excel spreadsheet (Bowel_Dataset_v1.3) completed by NHS staff 
(see Appendix).  The data provide information on patient characteristics (age, gender, height, 
weight); tumour and ĐůĂƐƐŝĨŝĐĂƚŝŽŶ  ?ƉƌŝŵĂƌǇƐŝƚĞ ?ƵŬĞƐ ?ƐƚĂŐŝŶŐ ?ŵĞƚĂƐƚĂƐĞƐ ? ?ĚĂƚĞƐ ?ŽƵƚĐŽŵĞƐĂŶĚ
complications associated with procedures (barium enema, colonoscopy, CT and MRI scans, 
ultrasounds) and interventions (elective and scheduled surgery, radiotherapy, chemotherapy, 
palliative care); complications of cancer, follow-up care (clinical status, recurrence of primary 
                                                          
1
 The bowel cancer NCA is likely to include a very small proportion of paediatrics, but for the purpose of the 
current study, this audit is considered to be in adults only.   
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tumour and metastasis spread, treatment morbidity); and survival status (date and morbidity code).  
There does not appear to be a patient questionnaire in the bowel cancer NCA. 
 
 
4.3.3 Comparing fields in bowel cancer NCA with variables used in existing HTAs  
The existing models in bowel cancer use survival curves for recurrence, progression and OS.  The 
NCA information on clinical interventions (tumour, treatment, follow-up) would provide some of the 
information required to compare alternative treatments.  The mortality date could be used to model 
overall mortality, and there may be sufficient detail to extract survival curves for progression and 
recurrence from the mandatory fields.  Side-effects and adverse events due to chemotherapy, 
radiotherapy and surgery are prevalent.  While there is some information on toxicity (treatment 
related morbidity: mild toxicity, moderate toxicity, severe toxicity, death due to toxicity) this field is 
non-mandatory (Table A7) and it is not clear if the level of detail collected would suffice to populate 
a model. 
 
Clinical variables such as American Society of Anesthesiologists classification (ASA) grade (a normal 
healthy patient, a patient with mild systemic disease, a patient with severe systemic disease, a 
patient with severe systemic disease that is a constant threat to life, a moribund patient who is not 
expected to survive without the operation, a declared brain-dead patient whose organs are being 
ƌĞŵŽǀĞĚ ĨŽƌĚŽŶŽƌƉƵƌƉŽƐĞƐ ?ŶŽƚŬŶŽǁŶ ?ĂŶĚƵŬĞƐ ? ƐƚĂŐĞ  ? ? ? ? ? ? ? ?ŶŽƚŬŶŽǁŶ ?ŵŝŐŚƚďĞ
used to case-mix patients when comparing performance or cost-effectiveness of interventions.  
However, DukĞ ?Ɛ ƐƚĂŐŝŶŐ ƌĞƋƵŝƌĞƐ ƉĂƚŚŽůŽŐŝĐ ĐŽŶĨŝƌŵĂƚŝŽŶ ĂŶĚ ŝƚ ŝƐ ŶŽƚĐůĞĂƌ ŝĨ ƚŚŝƐ ǁŽƵůĚ ďĞ
available for all patients in the audit. 
 
Patient related outcome measures are not currently collected in the bowel cancer NCA.  The 
inclusion of a preference-based HRQoL questionnaire (e.g. the EQ-5D), would be extremely 
informative, particularly as the existing HTAs do not in generally use preference-based data to 
weight survival due to a dearth of appropriate evidence in patients with bowel cancer.  As stated 
earlier, thĞ ƵƐĞ ŽĨ ƵŬĞ ?Ɛ ƐƚĂŐŝŶŐ ĂůŽŶŐƐŝĚĞ ƚŚĞ ƉƌĞĨĞƌĞŶĐĞ-based measure would be extremely 
useful evidence for use in economic models.  This approach would likely require an analysis to link 
the two variables but could potentially reduce the uncertainty in economic results.  There does not 
appear to be any suitable variable collected in the bowel cancer audit which might be used to 
generate proxy preference-based utility values using an existing function. 
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Assuming the mandatory fields have relatively high completion rates, with the exception of HRQoL, 
and toxicity, the information currently collected in the existing NCA would provide the majority of 
information required to model the cost-effectiveness of interventions and policies in bowel cancer.  
As previously noted, there is a dearth of preference-based HRQoL evidence in bowel cancer, and the 
collection of utilities within the NCA would be recommended as an important and valuable 
consideration.  It is not known if there are any ongoing studies in this area, but the bowel cancer 
NCA will be undergoing a retendering process later this year (2014) and it is possible that the new 
contract will include the collection of PROMS.[personal communication, Eleanor Bunn, Audit 
Coordinator, 13
th
 May 2014] 
 
 
4.4 Recommendations for bowel cancer   
The evidence base relating to the appropriateness of the EQ-5D in patients with bowel cancer is 
mixed and further validation is required.  All the evidence is in adults and while the NCA inclusion 
definition includes all patients with bowel cancer, the proportion of paediatrics is likely to be 
extremely small and is not considered in this section.  The evidence in the literature which could be 
used to populate the utility values in economic models is extremely poor (see Section 4.3).  With the 
exception of information on treatment related adverse events/complications, it is thought that the 
current NCA collects much of the information required to conduct economic evaluations.  However, 
as far as we are aware, there does not appear to be a patient questionnaire.  Potential 
recommendations (PR) and areas for future research (FR) are discussed below.  All suggested future 
research areas are indicative and would require a discussion and detailed proposal if required. 
 
Due to the extremely limited evidence base providing information of HRQoL in this patient group, it 
is recommended that consideration is given to including a preference-based measure in the NCA for 
bowel cancer.  This would involve developing a patient questionnaire suitable for patients with 
bowel cancer.  While it is recommended that the EQ-5D is considered in the first instance (PR.1), due 
to the equivocal evidence on the psychometric properties of this instrument in this patient 
population, it is also recommended that a psychometric assessment of the EQ-5D is conducted on 
the initial round of data collected (FR.1).  The inclusion of a cancer specific measure such as the 
EORTC QLQ-C30 and the associated colorectal module (QLQ-CR29) is also recommended (PR.2), to 
identify cancer specific issues which will be useful when comparing aross providers, and to inform 
future economic evaluations.   
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To assist in future economic evaluations, it is also recommended that consideration is given to 
ensuring the mandatory fields in the audit include some form of measure to assess the stage of the 
ĐĂŶĐĞƌ ?Ğ ?Ő ?ƵŬĞ ?ƐƐƚĂŐŝŶŐ ? ?WZ ?2).  This should be synchronised with the timing of collection of the 
HRQoL data.   In addition, the majority of patients will receive chemotherapy and the mandatory 
collection of treatment related adverse events is recommended (PR.3).  A thorough detailed 
inventory of the exact information collected in the NCA is required before recommendations relating 
to additional mandatory fields are suggested (PR4, FR.3). 
 
Table 4: Recommendations and associated future research for bowel cancer 
PR.1 Include the EQ-5D in future patient questionnaires alongside a condition specific measure 
such as the EORTC QLQ-C30 and the colorectal module (QLQ-CR29) 
FR.1 Assess the psychometric properties of the EQ-5D using the data collected in the bowel 
cancer audit 
PR.2 /ŶĐůƵĚĞ Ă ƐĞǀĞƌŝƚǇ ŵĞĂƐƵƌĞ ƐƵĐŚ ĂƐ ƵŬĞƐ ? ƐƚĂŐŝŶŐ  ?ƚŽ ďĞ ĐŽůůĞĐƚĞĚ ĂůŽŶŐƐŝĚĞ ƚŚĞ ,ZYŽ>
data) 
PR.3 Collect mandatory information on adverse events associated with chemotherapy regimens 
(plus radiotherapy adverse events, and surgical complications) 
PR.4 Include additional mandatory fields in the bowel cancer audit 
FR.3 Detailed analyses of fields currently collected in the bowel cancer audit to identify 
recommendations for future mandatory fields 
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5.  SUMMARY   
The following section provides an overview of the results presented within the individual sections of 
the report.  A summary of the evidence used to inform the conclusions for WP1.1 and WP1.2 is 
provided in Table 5.  This section provides an overview only and it is recommended that the 
preceding sections are used for details on particular conditions. 
 
5.1 Summary of evidence used to inform the conclusions for WP1.1 and WP1.2 
A reanalysis and update of an existing review (n=9 primary studies) provided mixed evidence 
regarding the construct validity and responsiveness of the EQ-5D. Acceptability, reliability and ceiling 
effects were not reported by the original review authors. In some cases, known group validity 
appeared good against both cancer specific and generic measures, whilst in others it was unable to 
detect differences between groups where condition specific measures (EORTC QLQ-C30 or QLQ-
CR38) could. One study reported convergent validity of the EQ-5D against TNM stages was low, as 
was the case for several other cancer specific and psychological symptom specific measures or 
subscales. However, some measures and subscales had moderate correlations. Responsiveness was 
also mixed, with the EQ-5D able to detect a change in health status over time in some cases, but not 
in others, where condition specific or symptom specific measures and subscales such as the HADS 
depression score, FACTC and EORTC measures did. It was concluded that the EQ-5D could not be 
recommended without further validation. A review of all alternative measures that could be used 
was not conducted, but it is recommended that the EQ-5D be used in conjunction with the EORTC-
C30, which has a UK utility tariff, and the colorectal module EORTC QLQ-CR29. 
 
Table 5: Summary of evidence supporting the psychometric properties of EQ-5D in all conditions 
 N Acceptability Reliability Construct Responsiveness Overall 
Measure KGV Convergent Change  
over 
time 
Ceiling  
Effect 
EQ-5D 9 NR  NR Mixed Poor Mixed NR Acceptable 
EORTC 
QLQ-C30 
EORTC 
QLQ-
CR38/29 
 The psychometric properties of these measures have not been reviewed in the 
current report 
N= number of studies used to inform conclusions, KGV: known group validity; NR, the existing review did not 
review this psychometric property;  
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5.2 Summary of evidence required for use in economic evaluations (WP1.3) 
The bowel cancer audit does not include a patient questionnaire thus PROMs are not currently 
collected and existing literature on preference-based data which could be used to inform formal 
economic evaluations is sparse.  The audit collects some of the information required to compare 
providers and economic evaluations such as surǀŝǀĂů ? ƉƌŽŐƌĞƐƐŝŽŶ ĂŶĚ ƐƚĂŐŝŶŐ ŽĨ ĚŝƐĞĂƐĞ  ?ƵŬĞƐ ?
stage).  However, key variables such as toxicity due to chemotherapy and adverse effects of surgery 
and radiotherapy are not currently mandatory fields.   
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Appendix 
The tables in this Appendix provide additional information for the reviews (WP1.1, 1.2 and 1.3) conducted for 
bowel cancer.  
 
Table A1: Quality assessment of Longworth et al 2014 for bowel cancer(34)   
Quality assessment criteria Compliance with criteria 
AMSTAR  
Was an a priori design provided? Yes 
Was there duplicate study selection and data 
extraction? 
No 
Were the methods used to combine the findings of 
the studies appropriate? 
Unclear - narrative synthesis conducted but no 
justification for lack of meta-analysis provided.  
Was the scientific quality of the included studies 
assessed and documented? 
Yes, but not by validated method. 
Was the scientific quality of the included studies used 
appropriately in formulating conclusions? 
Yes  W studies not excluded for quality reasons but 
quality assessment stated to be used for informing 
strength of evidence. 
Overall judgement of quality of review Good but only 1 reviewer. 
Quality of the searches Acceptable 
Strength of the evidence  
Were the conclusions robust and conclusive? No, conclusions were robust and conclusive for 
construct validity, but only one study was available 
with responsiveness data. 
Quantity of the evidence  
Was there enough data to be confident that any 
additional data published subsequently would be very 
unlikely to change the conclusions drawn? 
No  W only one study for responsiveness data. 
Adequacy of data reported  
Did the review provide sufficient data to allow 
integration of an update/assessment of the methods 
used? 
Yes 
Did the review assess EQ-5D in a way compatible with 
the aims of work package 1.1? 
Yes, construct validity (known groups or convergent) 
or responsiveness (effect sizes, standardised response 
means, or correlation with change scores on 
symptom measures). 
 
  
27 
 
Table A2: Characteristics of primary studies included in Longworth review (bowel cancer). Adapted from 
Longworth et al.(34) 
Author, year Sample 
size 
Condition Study 
design 
Study information Male/female 
(%) 
Mean age 
at 
baseline 
Anderson and 
Palmer, 
1998(10) 
545 Advanced 
colorectal cancer 
RCT Raltitrexed vs. 
Standard 5-
fluorouracil 
N/R N/R 
Doornebosch 
et al, 2007(5) 
62 T1 carcinoma 
after surgery 
(TEM), T1 to T3 
(35%)(TME) 
Cross-
sectional 
Total Mesorectal 
excision vs. 
Transanal 
Endoscopic 
microsurgery 
N/R N/R 
Doornebosch 
et al., 
2008(11) 
47 People with 
rectal cancer 
eligible for TEM 
Before-
after 
Transanal 
Endoscopic 
microsurgery 
N/R N/R 
Gosselink et 
al., 2006(6) 
204 People with 
rectal cancer in 
the middle or low 
third of the 
rectum after 
total mesorectal 
excision 
Cross-
sectional 
Abdominoperineal 
resection; 
Transanally double 
stapled low 
colorectal 
anastomosis; colo-
anal J-pouch 
anastomosis 
N/R N/R 
Hamashima, 
2002(7) 
110 Rectal cancer 
patients who had 
received surgery 
as their initial 
treatment 
Before-
after 
Surgery N/R N/R 
Janson et al., 
2007(8) 
285 Elective colon 
cancer patients 
with potentially 
curable cancer 
best treated by 
right or left 
hemicolectomy 
or sigmoid 
resection 
RCT Laparoscopic 
colon resection vs. 
open resection 
N/R N/R 
Sharma et al., 
2007 (4) 
104 Newly diagnosed 
colorectal cancer 
scheduled for 
elective open 
resection 
Before-
after 
Elective open 
resection 
N/R N/R 
Siena et al., 
2007(14) 
463 Metastatic 
colorectal cancer  
patients who had 
progressed on 
prior 
fluoropyrimidine, 
irinotecan and 
oxaliplatin 
RCT Panitumumab plus 
best supportive 
care vs. best 
supportive care 
alone 
N/R N/R 
Wilson et al., 
2006(9) 
210 Patients 
undergoing 
potentially 
curable open 
Before-
after 
Surgery N/R N/R 
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Author, year Sample 
size 
Condition Study 
design 
Study information Male/female 
(%) 
Mean age 
at 
baseline 
surgery for 
colorectal cancer 
RCT: randomised controlled trial; TEM: transanal endoscopic microsurgery; TME: total mesorectal excision;    
 
 
Table A3: Characteristics of primary studies included in Longworth review (bowel cancer). Adapted from 
Longworth et al.(34) 
Author, Year, 
Location 
EQ-5D Comparison 
measure 
Psychometric 
properties 
assessed 
Assessment of psychometric 
properties 
Anderson and 
Palmer, 1998, 
UK(10) 
EQ-5D UK RSCL Responsiveness Odds ratio for responses of EQ-
5D dimensions between 
baseline and week 5 and 15 
over the two groups 
Doornebosch et 
al, 2007, 
Netherlands(5) 
EQ-5D, 
EQ-VAS 
EORTC QLQ Known group 
validity (severity) 
EQ-5D scores according to 
intervention group 
Doornebosch et 
al., 2008, 
Netherlands(11) 
EQ-5D FIQL Responsiveness tŝůĐŽǆŽŶ ?ƐƐŝŐŶĞĚƌĂŶŬƚĞƐƚĂŶĚ
Mann-Whitney U test for 
change scores within or 
between groups. Spearman 
rank correlations between 
change scores. 
EQ-5D: Euro-QoL 5 dimensions; RSCL: Rotterdam symptom checklist; VAS: visual analogue scale; EORTC QLQ: 
European organisation for research and treatment of cancer core quality of life questionnaire; FIQL: faecal 
incontinence quality of life. 
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Table A4: Construct validity results for bowel cancer, adapted from Longworth et al 2014.(34)  
Author, year Method of measuring known 
groups validity 
Known group validity results 
Construct validity (known group) 
Doornebosh 
2007(5) 
EQ-5D, EORTC QLQ C30 and 
EORTC QLQ-CR38 scores 
according to intervention group 
No difference on EQ-5D scores between the three 
intervention groups.  
No difference in EORTC QLQ-C30 subscales scores 
between the three intervention groups. 
Significant difference in scores for EORTC QLQ-CR38 
between TEM and TME groups regarding defecation 
problems  W TEM patients had less defecation problems 
than TME patients (p<0.05). 
Gosselink 
2005(6) 
EQ-5D and EORTC scores 
according to intervention group 
Mean EQ-5D score for CPA group was significantly higher 
than the sex-age matched general population. 
Mean EQ-5D scores for LRA and APR groups were similar 
than the sex-age matched general population. 
EQ-5D scores did not differ between the three 
intervention groups. 
5 subscales of EORTC scores were significantly different 
between the three intervention groups . 
Hamashima 
2002(7) 
Significant differences in EQ-5D 
scores between patients with 
or without stoma 
EQ-5D scores for those with and without stoma groups 
were not significantly different. 
Janson 2007(8) EQ-5D and EORTC scores 
according to intervention group 
EQ-5D scores at baseline between intervention groups 
were not significantly different. 
EQ-VAS scores at baseline between intervention groups 
were not significantly different. 
EORTC QLQ-30 scores at baseline between intervention 
groups were not significantly different. 
Wilson 2006(9) EQ-5D scores by ECOG 
performance status groups 
EQ-VAS, SF-12 GH, SF-12 PCS, 
QLQ GH, FACT-C scores by 
ECOG performance status 
groups 
EQ-5D, scores were significantly different between ECOG 
PS status groups. 
EQ-VAS, SF-12 GH, SF-12 PCS, QLQ GH were significantly 
different between ECOG performance status groups. 
EQ-5D, total scores declined with advancing preoperative 
ECOG performance status. 
EQ-VAS, SF-12 GH, SF-12 PCS, QLQ-GH, FACT-C 
Doornebosch 
2008(11) 
EQ-5D scores vs FISI scores and 
FIQL scores pre and 6 months 
post surgery. 
 
 
EQ-5D scores were not affected by age and gender of the 
patients, surgical aspects and tumour characteristics.  
FIQL scores were not affected by age and gender of the 
patients, and surgical aspects and tumour characteristics. 
Construct validity (convergent) 
Sharma 
2007(4) 
Correlations between measures 
and TNM stage 
EQ-5D correlation with TNM stages is small and not 
statistically significant. 
( HADS anxiety, PANSS negative affect and FACT-
emotional wellbeing were all significantly moderate 
correlated with TNM stage) 
 EQ-5D: Euro-Qol 5 dimensions; EORTC QLQ: European organisation for research and treatment of cancer core 
quality of life questionnaire; TEM: transanal endoscopic surgery; TME: total mesorectal excision; CPA: colo-
anal J-pouch anastomosis; APR: abdominoperineal resection; LRA: transanally double stapled low colorectal 
anastomosis; ECOG: Eastern Cooperative Oncology Group; SF-12: Short-Form 12; FACT-C: functional 
assessment of cancer therapy  W colorectal; TNM: tumour, node, metastases; HADS: hospital anxiety and 
depression scale; PANSS: positive and negative syndrome scale.  
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Table A5: Responsiveness results for bowel cancer, adapted from Longworth et al 2014. (34) 
Author, year Method of measuring 
responsiveness  
Responsiveness results 
Anderson and 
Palmer 
1998(10) 
Odds ratio for responses of 
EQ-5D dimensions between 
baseline and week 5 and 15 
over the two groups  
 
Odds ratio for responses of 
RSCL dimensions between 
baseline and week 5 and 15 
over the two groups 
Week 2 (changes from baseline): 
RSCL scores (all dimensions and sub-divisions) significantly 
different in patients randomised to raltitrexed and 
patients randomised to 5-FU+LV arms with the exception 
of psychological symptoms and disease categories.  
EQ-5D scores (4 dimensions and general health questions) 
highly significantly different in favour of raltitrexed . 
Raltitrexed group three times less likely to have problems 
with mobility and usual activities than 5-FU+LV group (OR 
2.9 and p<0.02). Ralaxitred group at least twice as likely to 
have a better general health (OR 2.3, p<0.001) and 2 to 3 
times as capable of self-care as patients in the 5-FU+LV 
group but this result not significant.  
 
Week 10: 
No statistically significant differences between groups . 
Non-significant trends in favour or reltitrexed on the EQ-
5D scale and in total symptom advantages.  
Doornebosch 
2008(11) 
tŝůĐŽǆŽŶ ?Ɛsigned rank test 
and Mann-Whitney U test for 
change scores within or 
between groups. Spearman 
rank correlations between 
change scores. 
 
FISI mean scores showed significant post-op decrease. 
Greater decrease for patients with a tumour location 
within 7cm from the denatate line (p=0.01).  
FIQL showed a significant post-op improvement in two of 
the four domains (embarrassment and lifestyle). The 
domains of lifestyle, coping and behaviour and 
embarrassment were correlated with the FISI. 
 
Janson 2007(8) Mean changes of scores 
between intervention groups 
(MANOVA analysis of change 
over time). 
EQ-5D scores not significantly different between 
intervention groups.  
EORTC QLQ-C30 scores showed significant benefit of LCR 
at the 2 and 4 week assessments. At the 12 week 
assessment, this was borderline significant. Significant 
benefit of LCR for role function found at two week 
assessment. 
Sharma 
2007(4) 
Mean changes in EQ-5D scores 
before and after surgery. 
Mean changes in HADS, 
PANAS, FACT-EW, EQ-VAS 
scores before and after 
surgery. 
 
 
HADS depression score significantly higher in the 6 week 
post-discharge measure (3.6 vs 4.8, p<0.05) 
 
HADS anxiety, PANAS positive and PANAS negative affect, 
FACT-C total, FACT-C trial outcome index and EQ-5D were 
not significantly different postoperatively. 
 
 
 
Siena 2007(14) EQ-5D scores by intervention 
group, FCSI scores by 
intervention group 
 
FCSI change scores significant for both intervention and 
best supportive care groups.  
EQ-5D only found significant change in intervention group. 
 
RSCL: Rotterdam symptom checklist; FU: fluorouracil; LV: leucovonin; EQ-5D: EuroQoL 5 dimensions; FISI: 
faecal incontinence severity index; FIQL: faecal incontinence quality of life; EORTC QLQ: European organisation 
for research and treatment of cancer core quality of life questionnaire; LCR: laparoscopic colon resection; 
HADS: hospital anxiety and depression scale; PANAS: positive and negative affect scale; FACT-C: functional 
assessment of cancer therapy  W colorectal; FACT-EW: functional assessment of cancer therapy  W emotional 
well-being; FCSI: FACT colorectal symptom index.    
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Table A6: Mandatory fields collected in the bowel cancer NCA  
PATIENT
 
 NHS number, Date Of birth, Postcode (at diagnosis), Gender 
TUMOUR
 
 Organisation first seen, Date of diagnosis, Source of referral, Major site ICD10, Performance status, Care 
plan intent, Planned cancer treatment type, No cancer treatment reason, T category, N category, M 
category  
SURGERY
 
 Provider organisation, ASA grade, Cancer treatment curability, Date of surgery, Surgical urgency mode of 
operation, Consultant, Primary procedure, Surgical access  
PATHOLOGY 
 
  Status of circumferential excision margin, Number of nodes examined, Number of nodes positive, Final 
pathology T category, Final pathology N category, Final pathology radiology M category 
CHEMORADIOTHERAPY 
 
  Pre-op initial provider organisation, Pre-op initial cancer treatment modality,  Post-op provider 
organisation, Post-op cancer treatment modality 
PATIENT (Dataset refs: B1-B8) 
  NHS number, Originating organisation code, Updating organisation code, Uploading organisation code, 
Batch ID, Batch record ID, Sex, Height, Weight, Post mortem (Y/N) 
TUMOUR (Dataset refs: B9-B48) 
  NHS number, Care spell number, Originating organisation code, Updating organisation code, Uploading 
organisation code, Batch ID, Batch record ID, Place first seen organisation code, Date of clinical diagnosis, 
ICD10 major site code,  Synchronous sites (caecum, appendix, ascending colon, hepatic flexure, 
transverse colon, splenic flexure, descending colon, sigmoid colon, recto/sigmoid, rectum), Height of 
ƚƵŵŽƵƌĂďŽǀĞĂŶĂůǀĞƌŐĞ ?DŽĚŝĨŝĞĚƵŬĞƐ ?ƐƚĂŐŝŶŐ ?ůŝŶŝĐĂůŝŶƚĞƌǀĞŶƚŝŽŶĚĂƚĞ W colonoscopy, Colonoscopy 
complications, Clinical intervention date - barium enema, Patient procedure result - barium enema, CT 
colonography, Clinical intervention date - CT scan, Patient procedure result - CT scan, Clinical intervention 
date - 1st MRI scan, Patient procedure result -1st MRI scan T stage, Patient procedure result -1st MRI 
Scan N stage, 1st MRI scan margin threatened  W result, Clinical intervention date -2nd MRI Scan, Patient 
procedure result -2nd MRI scan T stage, Clinical intervention date - Endoanal ultrasound, Patient 
procedure result - endoanal ultrasound, Clinical intervention date - Abdominal ultrasound, Patient 
procedure result - abdominal ultrasound, Distant metastases: (liver, lung, bone, other) 
TREATMENT (Dataset refs: B49-B83)
 
 NHS number, Care spell number, Treatment ID, Originating organisation code, Updating organisation 
code, Uploading organisation code, Batch ID, Batch record ID, Surgery provider organisation code, Start 
date of 1st definitive procedure treatment, Reason no surgery performed, ASA grade, Thromboembolism 
prevention, Antibiotic infect prevention, Cancer treatment intent (curability),  Complications of cancer,  
Anaesthetist grade, Patient procedure (anastomosis), Patient Procedure (stoma), Date stoma closed, 
Surgical access, Type of bowel division at laparoscopy, Type of anastomosis at laparoscopy,  
Morbidity code (Major postoperative complication, Morbidity code (Major laparoscopic specific 
complication), Early port site complication, Excision margin (positivity of cut colon or rectum margin), 
Distance of tumour to nearest cut bowel margin (mm), Excision margin (circumferential margins), 
Distance between cancer and circumferential margins (mm), Perforation or serosal involvement, Distance 
between lower end of tumour and resection margin in rectal and rectosigmoid tumours (mm), Distance 
between lower end of cancer and dentate line in APER specimens (mm), Site specific staging classification 
(pathological, Dukes' Staging), Teletherapy type given, Teletherapy trial, Chemotherapy trial 
FOLLOW UP (Dataset refs: B84-B96)
 
  
NHS number, Care spell number, Follow up ID, Originating organisation code, Updating organisation code, 
Uploading organisation code, Batch ID, Batch record ID,  Organisation code (follow up provider), Mode of 
follow-up, Primary tumour status (local recurrence), Local recurrence diagnosed by, Wound recurrence, 
Port site recurrence, Site of distance spread 
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Table A7: Optional fields collected in bowel cancer NCA (WP1.3) 
PATIENT
a 
 Patient surname, Patient forename 
TUMOUR
a 
 Clinical nurse specialist indication, Synchronous cancer, Monitoring intent 
SURGERY
a 
 CPES anaerobic threshold, BMI, Immediate post-operative care 
PATHOLOGY 
a 
  No additional fields 
CHEMORADIOTHERAPY 
a 
  No additional fields 
PATIENT
b 
 
  Patient local identifier code, Patient forename, Patient surname, Postcode, Date of birth, Consultant 
code, Date of death, Cause of death 
TUMOUR
b
  
  
  
  
  
Date of diagnosis, Referral source, Diagnostic route, Date of referral receipt, Priority of referral to 
outpatients, Date of first hospital appointment, Patient procedure results  ? colonoscopy, Colonoscopy 
incomplete reason, Final pre-treatment T category, Final pre-treatment N category, Final pre-treatment 
M category, MDT discussion indicator 
TREATMENT
b 
 Colorectal nurse or stoma therapist seen, Date seen by colorectal nurse or stoma therapist, Procedure 
date (date of surgery), Theatre case start time (24hr), Surgical Urgency (mode of operation), Primary 
procedure name (OPCS), Code of responsible HCP (Surgeon GMC code), Grade of responsible HCP (grade 
of operating surgeon), Discharge date (hospital provider spell (Date of discharge or death), Organisation 
code (pathology provider), date specimen sample received, Investigation result date (date of report), 
Authorising pathologist GMC code, Service report status, Service report identifier, Synchronous cancer 
indicator, Invasive lesion site (cancer size, mm), Grade of differentiation, Histology (SNOMED), Nodes 
examined number (number of lymph nodes found), Nodes positive number (number of positive lymph 
nodes found), Cancer vascular or lymphatic invasion (extramural vascular invasion), T category 
(pathological), N category (pathological), M category (pathological), Site code of teletherapy treatment, 
Teletherapy consultant code, Start date teletherapy treatment course (radiotherapy start date), Sidte 
code (of cancer drug treatment (Hospital)), Consultant code, Drug treatment intent, Start date (anti-
cancer drug regiment) 
FOLLOW UP
b
 
 
    
Clinical assessment date (cancer, date of follow-up), Metastatic status dist spread, Treatment related 
morbidity 
a 
collected via an excel spreadsheet;
 b
Extracted from Pdf: National Bowel Cancer Audit Dataset v3.1 (19 
October 2009), BMI: body mass index, MDT: multi-disciplinary team 
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